摘要 |
<p>The invention provides the use of trioxopyrimidine compound having an inhibitory activity against MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 defined as a) IC50 value of less 5 µM for MMP-2, MMP-9 and MMP-14 each; b) a ratio of more than 100 for the IC50 values of MMP-1:MMP-2, MMP-1: MMP-9, MMP-1:MMP-14 and c) a ratio of more than 10 for the IC50 values of MMP-3:MMP-2, MMP-3: MMP-9 MMP-3:MMP-14, for the manufacturing of a medicament for the treatment or prevention of ocular pathologic angiogenesis.</p> |
申请人 |
F. HOFFMANN-LA ROCHE AG;UNIVERSITE DE LIEGE;FOIDART, JEAN-MICHEL;FRANKENNE, FRANCIS;KRELL, HANS-WILLI;LAMBERT, VINCENT;NOEL, AGNES;RAKIC, JEAN-MARIE |
发明人 |
FOIDART, JEAN-MICHEL;FRANKENNE, FRANCIS;KRELL, HANS-WILLI;LAMBERT, VINCENT;NOEL, AGNES;RAKIC, JEAN-MARIE |